A-Alpha Bio utilizes its AlphaSeq and AlphaBind platforms to generate high-resolution protein-protein interaction data at scale, enabling the discovery and engineering of effective protein therapeutics. The company addresses the challenge of limited high-quality interaction data, which hampers the understanding and treatment of diseases such as cancer and neurological disorders.

Canaery creates biologically enhanced working animals with amplified olfactory abilities to detect explosives, narcotics, pests, and disease biomarkers. Their system combines specialized training, wearable sensors, and adaptive algorithms to deliver real‑time alerts to handlers via portable devices, providing rapid, on‑site screening for security, pest‑control, and healthcare applications.

CellChorus provides the TIMING™ platform, a high‑throughput nanowell imaging system that uses visual AI to track and quantify migration, activation, cell‑cell interactions, cytotoxicity, and survival of thousands of individual immune cells in real time. The workflow generates single‑cell functional datasets that can be linked to multi‑omic profiling such as single‑cell RNA‑seq or flow cytometry, enabling researchers to identify and select the most effective cell candidates for immunotherapy development.

Checkerspot utilizes a proprietary WING® Platform to optimize microbes for the biomanufacturing of structural oils, providing sustainable alternatives to petroleum-based materials. This technology enables industries to develop high-performance products while reducing reliance on fossil fuels and meeting environmental standards.

Copernic designs novel heterogeneous catalysts for zero-carbon fuels and chemicals, leveraging scientific computing tools to accelerate development. The company focuses initially on reducing the cost of zero-carbon ammonia production for fertilizers and maritime energy applications. Their solutions are engineered to be economic, rapidly scaleable, and compatible with existing chemical industry infrastructure.

Cytovale has developed the IntelliSep test, an FDA-cleared diagnostic tool that analyzes the biomechanical properties of white blood cells from a standard blood draw to assess a patient's risk of sepsis within 8 minutes. This rapid detection addresses the critical challenge of timely diagnosis in sepsis, a condition that increases mortality by 8% for every hour treatment is delayed.

EnPlusOne Bio provides a flexible enzymatic platform to address the manufacturing limitations currently hindering the acceleration of RNA therapeutics. This platform enables unrestricted synthesis and manufacturing capacity while achieving higher cycle efficiencies for long RNA production. By accessing a broader RNA design space, the company facilitates the incorporation of novel, naturally occurring RNA modifications beyond those accessible through standard chemical synthesis.

Epana Bio offers a high‑throughput single‑cell multi‑omics and AI platform that maps patient‑specific immune cell dysfunction in autoimmune diseases to identify druggable molecular targets. The system automates design of tailored biologics or small‑molecule candidates and integrates rapid preclinical validation, enabling pharma and biotech partners to develop mechanism‑based therapies with reduced side effects.

Immusoft utilizes Immune System Programming (ISP™) to reprogram a patient's B cells into plasma cells that produce therapeutic proteins, effectively creating personalized biofactories for treatment. This technology addresses the need for sustained delivery of gene-encoded medicines for rare diseases, offering long-term therapeutic benefits from the patient's own cells.

Incendia Therapeutics is a clinical‑stage biotech that develops fully human monoclonal antibodies to remodel the tumor microenvironment (TME) and enable immune cell infiltration. Its lead candidate, PRTH‑101, inhibits DDR1 to reduce collagen‑mediated barriers and is being tested in a Phase 1c trial alone and with PD‑1 blockade for PD‑L1‑negative NSCLC and ICI‑refractory thymic carcinoma, aiming to improve the efficacy of checkpoint inhibitors in solid tumors.

Modern Meadow produces BIO-VERA, a bio-fabricated material made from proteins and polymers, offering a sustainable alternative to traditional materials like leather and synthetics. BIO-VERA integrates into existing manufacturing processes for industries like automotive, footwear, and fashion, providing a more environmentally friendly option without sacrificing performance.

Noetik develops frontier AI models trained on extensive multimodal tumor data to predict individual patient responses to cancer treatments. This platform enhances clinical trial enrichment by accurately identifying likely responders for specific therapies. The technology aims to improve drug positioning and accelerate the discovery of novel, human-relevant oncology targets.

This company develops immunotherapies by utilizing immune organoids and artificial intelligence to design drugs that function effectively in humans from the initial stages. Their platform aims to accelerate drug discovery timelines and reduce development costs by testing candidates in realistic, patient-matched disease models. By integrating human data early, they seek to deliver safer, more effective therapies with fewer side effects across diverse populations.

Passkey Therapeutics utilizes its Locksmith® platform, which employs AI-enhanced computational genetics, to identify synergistic pairs of biological pathways for therapeutic intervention. This technology enables the development of novel drug combinations and multifunctional drugs targeting complex diseases. The company focuses on creating a new class of synergistic therapies by moving beyond the single-target drug development paradigm.

Phantom Neuro develops a muscle-machine interface, the Phantom X, that enables lifelike control of robotic systems for individuals with limb difference. This technology merges neuroscience, AI, and robotics to create a natural extension of the human body. The system provides unprecedented control over prosthetics through muscle signals, enhancing human capability.

ShiraTronics develops a neuromodulation device that is implanted beneath the skin to provide continuous stimulation to specific nerves associated with chronic migraine. This technology aims to reduce the frequency and severity of migraine attacks for individuals who do not find relief through traditional medications.

STRM.BIO utilizes extracellular vesicles to deliver gene therapy, enhancing the efficiency and safety of treatment for patients with rare diseases. This approach aims to simplify the administration of gene therapies, making them more practical and accessible for global patient populations.

Surf Bio develops the Surf SnapShot™ technology to transform biologic delivery by enabling ultra-high concentration monoclonal antibody formulations. This proprietary polymer technology allows for subcutaneous injection of large doses in seconds, replacing lengthy intravenous infusions. The resulting patient-friendly delivery enables self-administration and potentially longer dosing intervals for biologics.

TFC Therapeutics is developing a monoclonal antibody technology that specifically targets and eliminates TMH cells, which are key drivers of cancer recurrence and metastasis. This approach activates the immune system to destroy these resilient cancer cells, offering a new treatment option for preventing cancer relapse.

Twelve utilizes electrochemistry to convert CO2, water, and renewable energy into hydrocarbons, effectively creating essential materials and fuels without fossil fuels. This technology addresses industrial emissions by providing a sustainable alternative to petrochemicals, enabling the production of high-quality products with zero net new emissions.

Vitra Labs is developing a novel in vitro fertilization process that induces oogenesis outside the ovary using proprietary cell culture techniques and bioinformatics for egg maturation. This approach aims to increase accessibility to IVF by reducing costs and simplifying the egg retrieval process for individuals facing infertility.

ZymoChem produces BAYSE™, the first fully bio‑based, biodegradable superabsorbent polymer that matches or exceeds the performance of conventional petroleum‑based SAPs used in diapers, feminine hygiene products, and other consumer goods. The material is manufactured at commercial scale from renewable feedstocks, offering manufacturers a drop‑in, high‑absorbency solution that reduces landfill persistence and carbon footprint without a green premium.